Clinical Trial Update: A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial of intermittent oral dosing of ASP1517 in ESA-untreated chronic kidney disease patients with anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ASP1517

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED